{
    "Clinical Trial ID": "NCT00617942",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Cohort 1",
        "[Not Specified]",
        "INTERVENTION 2: ",
        "  Cohort 2",
        "[Not Specified]"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically documented adenocarcinoma of the breast",
        "  ANC > 1000 cells",
        "  Female; age > 18; Zubrod PS 0-1",
        "  Platelets > 100,000",
        "  Stage IIA-IIIB disease",
        "  Total bilirubin < or = ULN",
        "  No evidence of metastatic disease Not pregnant or lactating",
        "  No prior systemic therapy for this breast cancer",
        "  Serum Creatinine < 1.5 mg/dl or Creat Cl > 30 ml/min",
        "  Serum ALT < 2.5 x ULN",
        "  ER, PR and HER2 status required",
        "  LVEF (MUGA/echo)WNL",
        "  No baseline > 2 neuropathy",
        "  Hemoglobin > 9.0 gm/dl",
        "  HER2+, defined by IHC 3+ or FISH ratio > 2.0"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Patients With Complete Pathologic Response Rate, Observed Following Treatment With q3week Carboplatin, Weekly Abraxane and Weekly Trastuzumab in Resectable and Unresectable LABC;",
        "  These numbers represent patients with a RCB score of zero (0). RCB stands for residual cancer burden.",
        "Time frame: 1 year",
        "Results 1: ",
        "  Arm/Group Title: Cohort 1",
        "  Arm/Group Description: [Not Specified]",
        "  Overall Number of Participants Analyzed: 37",
        "  Measure Type: Number",
        "  Unit of Measure: participants  12",
        "Results 2: ",
        "  Arm/Group Title: Cohort 2",
        "  Arm/Group Description: [Not Specified]",
        "  Overall Number of Participants Analyzed: 23",
        "  Measure Type: Number",
        "  Unit of Measure: participants  13"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 7/37 (18.92%)",
        "  gr 3port infection, 1/37 (2.70%)",
        "  flu 1/37 (2.70%)",
        "  Febrile Neutropenia 1/37 (2.70%)",
        "  gr 4 sepsis, intubated  [1]1/37 (2.70%)",
        "  Diarrhea gr 2, Nausea gr 3, infection gr 3 1/37 (2.70%)",
        "  infection normal ANC/viral grade 1 1/37 (2.70%)",
        "  Dehydration 3, Diarrhea 3, Vomit 3, HGB3, Nausea 3, K 3, Dyspnea 2 1/37 (2.70%)",
        "  gr 3cellulitis - breast 1/37 (2.70%)",
        "Adverse Events 2:",
        "  Total: 8/23 (34.78%)",
        "  gr 3port infection, 0/23 (0.00%)",
        "  flu 0/23 (0.00%)",
        "  Febrile Neutropenia 0/23 (0.00%)",
        "  gr 4 sepsis, intubated  [1]0/23 (0.00%)",
        "  Diarrhea gr 2, Nausea gr 3, infection gr 3 0/23 (0.00%)",
        "  infection normal ANC/viral grade 1 0/23 (0.00%)",
        "  Dehydration 3, Diarrhea 3, Vomit 3, HGB3, Nausea 3, K 3, Dyspnea 2 0/23 (0.00%)",
        "  gr 3cellulitis - breast 0/23 (0.00%)"
    ]
}